Please assess the completion status of the following clinical trial:

Trial Title: Karma Intervention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Attending the national mammography screening program, i.e. aged 40-74 and has performed a screening mammogram maximum 3 months prior to study inclusion~* Having a measurable mammographic density, i.e. ≥4.5 % density (volumetric) measured by Volpara~* Informed consent must be signed before any study specific assessments have been performed~Exclusion Criteria:~* Pregnancy at start, during time of study medication and up to 3 months after quitting study medication~* Any previous or current diagnosis of breast cancer (including carcinoma in situ)~* Mammographic BI-RADS code 3 or above at baseline mammography, or at a diagnostic mammography during time of treatment (the first 6 months of the study)~* Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in situ cancer of the cervix~* Currently using oral oestrogen and progesterone based hormone replacement therapy~* Current use of hormone contraceptive with hormones, e.g. hormonal contraceptive pills, or progesterone implants. Hormonal intrauterine devices are accepted.~* A history of thrombo-embolic disease such as embolies, deep vein thrombosis, stroke, TIA or cardiac arrest.~* Known APC (Activated protein C )- resistance, an inherited hemostatic disorder~* A history of major surgery of the breast, e.g. reduction or enlargement, which might affect density measurements~* Women who have an increased risk of venous thrombosis due to immobilization, e.g. using wheelchair~* Known uncontrolled diabetes~* Hypertension at baseline, defined as systolic pressure higher than 140 mm Hg and diastolic higher than 90 mm Hg~* Use of drugs that interfere with CYP2D6 expression such as Seroxat (paroxetine), Fontex (fluoxetin) and Zyban / Voxra (bupropion)~* Use of Waran (warfarin)~* Non-medical approved drugs against hot-flashes including phytooestrogen~* Not able to understand study information and/or informed consent

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- 20 mg tamoxifen (Type: ACTIVE_COMPARATOR): None
- 10 mg tamoxifen (Type: EXPERIMENTAL): None
- 5 mg tamoxifen (Type: EXPERIMENTAL): None
- 2.5 mg tamoxifen (Type: EXPERIMENTAL): None
- 1 mg tamoxifen (Type: EXPERIMENTAL): None
- 0 mg tamoxifen (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).